EV/Sales (Enterprise Value to Revenue) is the valuation metric of last resort — and also the right starting point when a company's earnings are too distorted, too negative, or too early-stage to use P/E or EV/EBITDA. For high-growth technology, pharmaceutical, and capital-intensive companies in their early operational phase, EV/Sales is the only reliable cross-company valuation comparison available. Understanding when to use it — and when not to — is one of the most underappreciated screener skills.
Last updated: June 2026.
What EV/Sales measures
EV/Sales = Enterprise Value ÷ Annual Revenue
Where Enterprise Value = Market Capitalisation + Net Debt (Total Debt minus Cash).
EV/Sales answers a simple question: how many euros does the market pay per euro of annual revenue? A company with €1B in revenue and €5B EV is trading at 5x EV/Sales — the market is paying €5 for each €1 of annual revenue.
Unlike P/E or EV/EBITDA, EV/Sales requires no profitability. A company with negative EBITDA and no earnings still has revenue — so EV/Sales can be calculated and compared even when earnings-based multiples are undefined.
When to use EV/Sales
1. When earnings are negative or distorted by investment
A high-growth software company investing heavily in sales and marketing may generate €100M in revenue with €-20M EBITDA. P/E is undefined; EV/EBITDA is negative and meaningless. EV/Sales — say, 8x on €100M revenue — is the only standardised valuation anchor.
Similarly, a pharmaceutical company that generates €300M in revenue but spends €200M on R&D will show thin or negative EBIT margins despite a potentially very profitable underlying product franchise.
2. When comparing companies at different investment stages
Two biotech companies in the same therapeutic area — one with €500M revenue and positive EBITDA, one with €50M revenue but investing heavily in pipeline expansion — cannot be meaningfully compared on EV/EBITDA. EV/Sales allows a directional valuation comparison even when profitability diverges.
3. For high-gross-margin businesses
EV/Sales is most meaningful when gross margins are high and relatively consistent across peers. A SaaS software company with 80% gross margins at 8x EV/Sales may be cheaper than a low-gross-margin retailer at 0.3x EV/Sales — because the underlying unit economics are incomparable.
Rule of thumb: EV/Sales makes sense when gross margins are above 40–50%. Below that, a low EV/Sales multiple may simply reflect genuinely low business quality.
4. For early-stage growth companies
Pre-profit companies growing revenue 30–60% per year cannot be valued on current earnings. EV/Sales — contextualised with revenue growth rate — provides a framework: a company at 15x EV/Sales growing revenue 50% per year is cheaper than one at 10x EV/Sales growing 10% per year.
When NOT to use EV/Sales
For mature industrial or consumer companies: A cement company at 2x EV/Sales with 8% EBIT margins is very differently valued from a software company at 2x EV/Sales with 70% gross margins. Using EV/Sales for capital-intensive, low-margin businesses misses the crucial dimension of profitability.
As a substitute for profitability assessment: EV/Sales never tells you whether a company is actually a good business — only how the market prices its revenue. Two companies at 5x EV/Sales can be wildly different: one with 60% gross margins growing at 30%, another with 20% gross margins declining 5%.
For financials: Banks and insurance companies don't have "revenue" in the same sense — interest income or premiums written are not comparable to product or service revenue. EV/Sales is not applicable to financial sector stocks.
EV/Sales benchmarks by sector in Europe
| Sector | Typical EV/Sales range | Notes |
|---|---|---|
| Enterprise software / SaaS | 4–15x | Gross margins 70–85%; growth premium |
| Healthcare / pharma (large cap) | 2–6x | Margins vary by R&D cycle |
| Biotech (pre-profit) | 5–20x | Valued entirely on pipeline probability |
| Medtech | 2–5x | Recurring consumable revenue valued at premium |
| Technology hardware | 1–3x | Lower margins than software |
| Consumer goods (branded) | 1–3x | Stable but lower margin than software |
| Industrials | 0.5–2x | Capital intensive, cyclical |
| Retail | 0.1–0.5x | Low margins, high revenue scale |
| Energy | 0.3–1x | Commodity-price-driven, low net margins |
Values represent typical ranges; actual multiples vary with growth rates and current margin cycle.
The EV/Sales + gross margin combination
The most effective way to use EV/Sales for screening is to combine it with gross margin:
EV/Sales ÷ Gross Margin (sometimes called the "Revenue Efficiency Ratio"): adjusts the sales multiple for the underlying quality of each euro of revenue. A company with 80% gross margins at 8x EV/Sales has a ratio of 0.10; a company with 40% gross margins at 8x EV/Sales has a ratio of 0.20 — the first company is cheaper on a quality-adjusted basis.
This combination works well for cross-sector comparisons within the same broad category (e.g., comparing European SaaS companies, or comparing medtech businesses).
EV/Sales for European pharma: the most practical application
Large-cap European pharma is the single most important use case for EV/Sales in European equity markets. The reason: pharmaceutical earnings are severely distorted by R&D investment cycles.
Sanofi: €45B revenue, heavy pipeline investment depressing near-term margins. EV/Sales of 2–3x provides a more stable comparison point than P/E, which fluctuates with restructuring charges and R&D timing.
AstraZeneca: Revenue growing 15–20% annually from pipeline launches. EV/Sales of 4–6x reflects the premium for proven pipeline productivity.
Generic pharma companies (Teva, Hikma, Stada pre-private): EV/Sales of 0.5–1.5x reflects the commoditisation of generic drugs and competitive pressure on pricing.
Pharma EV/Sales screen
| Filter | Value |
|---|---|
| Sector | Healthcare / Pharmaceuticals |
| Market cap | > €1B |
| EV/Sales | < 4 |
| Gross margin | > 50% |
| Revenue growth (3yr) | > 5% |
| Sort by | EV/Sales ascending |
EV/Sales for European technology and software
European listed technology includes:
Enterprise software (SAP, Dassault Systèmes, Sage, Temenos, Amadeus IT): High gross margins (60–80%), sticky recurring revenue, appropriate for EV/Sales multiples of 4–10x depending on growth.
Semiconductors (ASML, BE Semiconductor, STMicroelectronics, Infineon): Capital-intensive manufacturers with cyclical revenue. EV/Sales of 4–15x for ASML-level dominant technology positions; 1–3x for more commoditised chip production.
Technology services (Capgemini, Atos, Sopra Steria): Lower-margin services businesses. EV/Sales of 0.5–1.5x; margins and client concentration quality matter more than the multiple itself.
Practical EV/Sales screen for European growth companies
| Filter | Value |
|---|---|
| Market cap | > €200M |
| EV/Sales | < 8 |
| Gross margin | > 40% |
| Revenue growth (3yr) | > 10% |
| Sort by | EV/Sales ascending |
This screen surfaces European growth companies at relatively modest sales multiples with genuine revenue growth and healthy unit economics — the overlap of growth and reasonable valuation.
Bottom line
EV/Sales is the right metric for companies where earnings are negative, distorted, or irrelevant to the core valuation story. It works best when gross margins are high and consistent across the comparison set, and when combined with a revenue growth context.
For European investors, the most practical applications are large-cap pharma (where R&D investment distorts P/E), software and SaaS companies (where growth investment depresses near-term profits), and medtech (where recurring revenue quality should be reflected in the EV relative to total sales). Used with gross margin as a quality adjuster, EV/Sales is a genuinely useful tool in the European equity screener's toolkit.
Frequently asked questions
Is a low EV/Sales ratio always good?
No — a low EV/Sales ratio means the market is paying little per euro of revenue, but this may be appropriate for a low-margin business rather than cheap for a high-quality one. A retailer at 0.3x EV/Sales with 5% gross margins is not more attractive than a software company at 6x EV/Sales with 75% gross margins. Always contextualise EV/Sales with the gross margin and growth rate of the business.
What EV/Sales ratio is considered cheap for European software?
European enterprise software companies typically trade at 4–10x EV/Sales, with the range varying by growth rate and profitability. A well-regarded European SaaS company growing revenue 15%+ per year might trade at 6–8x and be considered fairly valued. Below 4x EV/Sales for a growing, high-gross-margin software company generally signals the market is pricing in either decelerating growth or structural competitive threats worth investigating.
How is EV/Sales different from P/S (Price-to-Sales)?
P/S uses only market capitalisation in the numerator, while EV/Sales uses enterprise value (market cap + net debt − cash). EV/Sales is more accurate for cross-company comparisons because it accounts for different capital structures — a company with €1B in net debt is not equivalent to a debt-free company just because they have the same market cap. For companies with significant leverage or large cash balances, EV/Sales and P/S can diverge substantially.
Can EV/Sales be used for screening European biotech companies?
Yes — for pre-profit biotech companies with commercial-stage products, EV/Sales provides a valuation anchor where EV/EBITDA and P/E are undefined. The challenge is that early-stage biotech revenue is often from a single product launch rather than a stable franchise, so EV/Sales multiples of 10–30x on small revenue figures are common and don't carry the same meaning as 10–30x on a mature SaaS business. For biotech screening, combine EV/Sales with pipeline stage and cash runway as qualitative filters.
Screen European stocks by EV/Sales → — free, no account required. Filter by EV/Sales, gross margin, revenue growth, and more across all European exchanges.